Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 15/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757655 | 0.91 | PTGDR2 (0.44) | PTGDR2KDM4E | |
| SCHEMBL1757563 | 0.91 | PTGDR2 (0.64) | PTGDR2 | |
| SCHEMBL1757514 | 0.79 | PTGDR2 (0.62) | PTGDR2KDM4EAKR1A1AKR1B1PTGIR | |
| SCHEMBL1783309 | 0.72 | PTGDR2 (0.71) | PTGDR2PTGIRPTGDR | |
| SCHEMBL4761775 | 0.72 | PTGDR2 (0.79) | PTGDR2PTGIRPTGDR | |
| Water SCHEMBL11291624 | 0.71 | PTGDR2 (0.73) | PTGDR2KDM4EAKR1A1AKR1B1 | |
| SCHEMBL1757517 | 0.70 | PTGDR2 (0.59) | PTGDR2 | |
| SCHEMBL1758136 | 0.70 | PTGDR2 (1.00) | PTGDR2PTGDR | |
| SCHEMBL4559216 | 0.70 | ALDH1A1 (0.62) | PTGDR2KDM4EAKR1A1AKR1B1 | |
| SCHEMBL1757106 | 0.69 | PTGDR2 (1.00) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | PTGDR2 13/4885KDM4E 4693/4885AKR1A1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.